Rapamycin Induces Heme Oxygenase-1 in Human Pulmonary Vascular Cells
- 18 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (6) , 911-916
- https://doi.org/10.1161/01.cir.0000048191.75585.60
Abstract
Background— Rapamycin is an immunosuppressive agent with antiproliferative properties against not only lymphocytes but also vascular endothelial and smooth muscle cells, and it reduces the fibroproliferative response to vascular injury. Heme oxygenase-1 (HO-1) has also been shown to have graft protective effects and to inhibit vascular remodeling. In this study, we evaluated whether there is an interaction between rapamycin and HO-1. Methods and Results— In human pulmonary artery endothelial or smooth muscle cells, HO-1 expression was evaluated in response to rapamycin or wortmannin, an inhibitor of the upstream modulator of mammalian target of rapamycin (mTOR) PI-3K. We also evaluated whether the inhibitory actions of rapamycin on platelet-derived growth factor–dependent proliferation was mediated by HO using the chemical inhibitor tin protoporphyrin. Rapamycin induced HO-1 expression in both pulmonary endothelial and smooth muscle cells, whereas no to little increase was seen in response to another immunosuppressive agent, cyclosporin A. HO-1 expression was also increased in response to wortmannin, suggesting that the PI-3K–mTOR pathway is required for this induction. Inhibition of HO activity resulted in a loss of the antiproliferative activity of rapamycin in growth factor–stimulated smooth muscle cells. Conclusions— The induction of HO-1 expression by rapamycin and, more importantly, the effects of tin protoporphyrin, an inhibitor of HO activity, on the antiproliferative actions of rapamycin suggest that the effects of rapamycin may be, at least in part, modulated by its actions on HO-1.Keywords
This publication has 27 references indexed in Scilit:
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Lung Transplantation and Bronchiolitis Obliterans: An Evolution in UnderstandingImmunologic Research, 2001
- Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injuryJournal of Clinical Investigation, 1999
- Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.Journal of Clinical Investigation, 1997
- Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environmentNature Medicine, 1997
- EFFECTS OF RAPAMYCIN ON GROWTH FACTOR-STIMULATED VASCULAR SMOOTH MUSCLE CELL DNA SYNTHESIS INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR AND PLATELET-DERIVED GROWTH FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506Transplantation, 1995
- Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progressionCell, 1993
- Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signalCell, 1993
- Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycleJournal of Cellular Physiology, 1993
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975